Keith A. Pappa

2.8k total citations · 1 hit paper
36 papers, 1.5k citations indexed

About

Keith A. Pappa is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Keith A. Pappa has authored 36 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 23 papers in Virology and 7 papers in Emergency Medicine. Recurrent topics in Keith A. Pappa's work include HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (23 papers) and HIV/AIDS Research and Interventions (10 papers). Keith A. Pappa is often cited by papers focused on HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (23 papers) and HIV/AIDS Research and Interventions (10 papers). Keith A. Pappa collaborates with scholars based in United States, United Kingdom and Spain. Keith A. Pappa's co-authors include Brian Wynne, Catherine Granier, Sharon Walmsley, Sherene Min, Antonio Antela, Nathan Clumeck, Uriel Sandkovsky, Garrett Nichols, Franco Maggiolo and Dan Duiculescu and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Keith A. Pappa

35 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

2013 593 citations Sharon Walmsley, Antonio Antela et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keith A. Pappa United States	16	1.3k	986	394	215	129	36	1.5k
Franco Maggiolo Italy	12	1.0k 0.8×	837 0.8×	341 0.9×	280 1.3×	135 1.0×	28	1.3k
Jaime Andrade‐Villanueva Mexico	18	1.8k 1.4×	1.3k 1.3×	581 1.5×	329 1.5×	210 1.6×	64	2.1k
Tiziana Quirino Italy	22	841 0.6×	493 0.5×	557 1.4×	331 1.5×	188 1.5×	60	1.5k
Scott Brun United States	11	1.2k 0.9×	933 0.9×	346 0.9×	122 0.6×	47 0.4×	20	1.4k
Barbara Gripshover United States	15	809 0.6×	627 0.6×	413 1.0×	293 1.4×	116 0.9×	48	1.2k
Brian Woodfall United States	20	1.8k 1.4×	1.4k 1.4×	208 0.5×	363 1.7×	186 1.4×	29	1.9k
Peter Jensen United States	12	838 0.6×	515 0.5×	571 1.4×	245 1.1×	111 0.9×	14	1.3k
Richard Lalonde Canada	20	1.4k 1.1×	859 0.9×	298 0.8×	872 4.1×	63 0.5×	49	1.9k
Akil Jackson United Kingdom	20	686 0.5×	525 0.5×	228 0.6×	197 0.9×	79 0.6×	52	888
Pieter L. Meenhorst Netherlands	29	1.7k 1.3×	1.3k 1.4×	349 0.9×	567 2.6×	167 1.3×	51	2.3k

Countries citing papers authored by Keith A. Pappa

Since Specialization

Citations

This map shows the geographic impact of Keith A. Pappa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith A. Pappa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith A. Pappa more than expected).

Fields of papers citing papers by Keith A. Pappa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith A. Pappa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith A. Pappa. The network helps show where Keith A. Pappa may publish in the future.

Co-authorship network of co-authors of Keith A. Pappa

This figure shows the co-authorship network connecting the top 25 collaborators of Keith A. Pappa. A scholar is included among the top collaborators of Keith A. Pappa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith A. Pappa. Keith A. Pappa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wyk, Jean van, F. Ajana, Fiona Bisshop, et al.. (2021). Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study). HIV Medicine. 22. 28–28.

Pittaras, Theodoros, et al.. (2018). Antibiotic resistance profiles from isolated bacteria in outpatient infertility clinic in Greece. 17(2). 23–30. 1 indexed citations

Tebas, Pablo, Princy Kumar, Charles B. Hicks, et al.. (2015). Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 29(18). 2459–2464. 27 indexed citations

Raffi, François, Anita Rachlis, Cynthia Brinson, et al.. (2014). Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS. 29(2). 167–174. 43 indexed citations

Walmsley, Sharon, Antonio Antela, Nathan Clumeck, et al.. (2013). Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection. New England Journal of Medicine. 369(19). 1807–1818. 593 indexed citations breakdown →

D’Aquila, Richard T., Anna María Geretti, Joseph Horton, et al.. (2010). Tenofovir (TDF)-Selected or Abacavir (ABC)-Selected Low-Frequency HIV Type 1 Subpopulations During Failure with Persistent Viremia as Detected by Ultradeep Pyrosequencing. AIDS Research and Human Retroviruses. 27(2). 201–209. 15 indexed citations

Ross, Lisa, Winkler G. Weinberg, Edwin DeJesus, et al.. (2010). Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected Patients. AIDS Research and Human Retroviruses. 26(4). 407–417. 8 indexed citations

Hicks, Charles B., Edwin DeJesus, Louis Sloan, et al.. (2009). Comparison of Once-Daily Fosamprenavir Boosted with Either 100 or 200 mg of Ritonavir, in Combination with Abacavir/Lamivudine: 96-Week Results from COL100758. AIDS Research and Human Retroviruses. 25(4). 395–403. 17 indexed citations

Ha, Belinda, Qiming Liao, Lynn P. Dix, & Keith A. Pappa. (2009). Virologic Response and Safety of the Abacavir/Lamivudine Fixed-Dose Formulation as Part of Highly Active Antiretroviral Therapy: Analyses of Six Clinical Studies. HIV Clinical Trials. 10(2). 65–75. 8 indexed citations

10.

Smith, Kimberly Y., Winkler G. Weinberg, Edwin DeJesus, et al.. (2008). Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Research and Therapy. 5(1). 5–5. 79 indexed citations

11.

Kumar, Princy, Melanie Thompson, Karen T. Tashima, et al.. (2006). A prospective, 96‐week study of the impact of Trizivir^®, Combivir^®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity. HIV Medicine. 7(2). 85–98. 60 indexed citations

12.

Goetz, Matthew Bidwell, Monique R. Ferguson, Xueliang Han, et al.. (2006). Evolution of HIV Resistance Mutations in Patients Maintained on a Stable Treatment Regimen After Virologic Failure. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(5). 541–549. 16 indexed citations

13.

Nadler, Jeffrey P., Joseph Gathe, Richard B. Pollard, et al.. (2003). Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. BMC Infectious Diseases. 3(1). 10–10. 11 indexed citations

14.

Ciociola, Arthur A., et al.. (2001). Nonprescription Doses of Ranitidine Are Effective in the Relief of Episodic Heartburn. American Journal of Therapeutics. 8(6). 399–408. 5 indexed citations

15.

Ciociola, Arthur A., et al.. (2001). A Study of the Nonprescription Drug Consumer's Understanding of the Ranitidine Product Label and Actual Product Usage Patterns in the Treatment of Episodic Heartburn. American Journal of Therapeutics. 8(6). 387–398. 7 indexed citations

16.

Miner, Philip B., et al.. (1998). Meal Type Affects Heartburn Severity. Digestive Diseases and Sciences. 43(3). 485–490. 21 indexed citations

17.

Pappa, Keith A., et al.. (1998). A double-masked, placebo-controlled study of the efficacy and safety of premeal ranitidine in the prevention or reduction of heartburn. Current Therapeutic Research. 59(7). 454–466. 3 indexed citations

18.

Jacobs, R. F., et al.. (1993). Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children. Infection. 21(4). 223–228. 20 indexed citations

19.

Miles, Michael V., Steven H. Grossman, Keith A. Pappa, et al.. (1990). Pharmacokinetics of Oral and Transdermal Triprolidine. The Journal of Clinical Pharmacology. 30(6). 572–575. 5 indexed citations

20.

Pappa, Keith A.. (1990). The clinical development of mupirocin. Journal of the American Academy of Dermatology. 22(5). 873–879. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact